Psyence Biomedical Ltd. has approved a put option agreement with PsyLabs, a leading manufacturer of pharmaceutical-grade psychedelic compounds. Under the agreement, PsyLabs is granted the right, but not the obligation, to require Psyence BioMed to make an additional equity investment in PsyLabs through a share-for-share exchange at fair market value, subject to specified terms and conditions. This arrangement is part of a broader strategic relationship, which also includes licensing access to PsyLabs’ manufacturing capabilities. The agreement was reviewed and ratified by a special committee of independent directors, with an independent third-party valuation considered in the decision. Key executives from Psyence BioMed collectively hold less than 13% of PsyLabs' outstanding shares. The transaction is structured to secure reliable supply and commercial alignment while preserving Psyence BioMed’s near-term financial flexibility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-016391), on February 13, 2026, and is solely responsible for the information contained therein.